Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 102 Neoplasm Metastasis 26 Neoplasms 15 Brain Neoplasms 13 Prostatic Neoplasms 10 Endometrial Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Ovarian Neoplasms 7 Glioblastoma 7 Glioma 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Head and Neck Neoplasms 5 Colorectal Neoplasms 5 Breast Diseases 5 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Sarcoma, Ewing 3 Osteosarcoma 3 Neoplasms by Site 3 Multiple Myeloma 3 Meningioma 3 Melanoma 3 Liposarcoma 3 Carcinoma, Renal Cell 3 Unilateral Breast Neoplasms 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Fulvestrant 1 Epirubicin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × abemaciclib × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡